Mf. Yuen et al., Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy, HEPATOLOGY, 34(4), 2001, pp. 785-791
Factors associated with hepatitis B virus (HBV) DNA breakthrough and the si
gnificance of YMDD variants without the presence of wild-type YMDD during p
rolonged lamivudine treatment are unknown. We studied the amino acid sequen
ce of codon 552 (YMDD motif) and codon 528 by means of a line probe assay i
n 159 chronic HBV patients (median follow-up 29.6 months). Pretreatment HBV
DNA levels and alanine transaminase (ALT) levels correlated inversely with
the time to HBV DNA breakthrough with YMDD variants (r = -0.46, P =.001; r
= -0.45, P =.001 respectively). Patients harboring YMDD variants 3 months
before HBV DNA breakthroughs had higher HBV DNA breakthrough levels compare
d with those without YMDD variants 3 months before HBV DNA breakthroughs (1
8.9 X 10(6) vs. 5.4 X 10(6) copies/mL, P = .007). Patients with HBV DNA bre
akthroughs had higher percentages of YMDD variants without the presence of
wild-type YMDD compared with patients without HBV DNA breakthrough (25.6% v
s. 9%, P = .007 for single M552I variant; 20.9% vs. 8.1%, P = .026 for sing
le M552V variant; 30.2% vs. 9.9%, P = .004 for M552I/M552V variants). Patie
nts with HBV DNA levels of more than 10(3) copies/mL after 6 months of lami
vudine therapy had a 63.2% chance of subsequently developing YMDD variants.
HBeAg seroconversion occurred in 2 patients after the emergence of YMDD va
riants. Only one patient developed YMDD variant after HBeAg seroconversion.
There was no increase in the rate of development of YMDD variants or L528M
mutation in patients receiving lamivudine 25 mg daily or famciclovir 500 m
g 3 times a day before being given lamivudine 100 mg daily.